Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(4 years from now) | |
US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(5 years from now) | |
US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(5 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(5 years from now) | |
US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(5 years from now) | |
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(7 years from now) | |
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 28, 2026 |
ODE* (ODE*) | Apr 7, 2024 |
Pediatric Exclusivity (PED) | Oct 7, 2024 |
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
Dosage: PELLETS;ORAL
56
United States
21
European Union
20
Japan
17
China
14
Hong Kong
12
Spain
12
Canada
12
Singapore
11
Korea, Republic of
10
Brazil
9
New Zealand
9
Chile
9
Israel
9
Portugal
9
Taiwan
8
Argentina
8
Mexico
7
Poland
7
EA
7
Australia
7
South Africa
7
Slovenia
6
Colombia
5
Uruguay
5
Denmark
5
Croatia
5
Cyprus
5
Hungary
4
Philippines
4
Russia
4
Peru
4
Costa Rica
4
Ecuador
4
Lithuania
3
Malaysia
3
RS
3
Germany
3
Ukraine
3
ME
2
Moldova, Republic of
2
Morocco
2
San Marino
1
Turkey
1
AP
1
Norway
1
Netherlands
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic